2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 268

Applications of Salivary Gland Ultrasonography in Sjögren Syndrome and Sicca Symptoms: A Single Center Experience
Abstract Number: 269

Prevalence of Pneumococcal Vaccination in Rheumatologic Patients with Community Acquired Pneumonia. Biobadasar Registry
Abstract Number: 270

HIV Infection and Avascular Necrosis in the Antiretroviral Era
Abstract Number: 271

The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Abstract Number: 272

The Difference in the Clinical Characteristics between Cytomegalovirus Disease and Asymptomatic Cytomegalovirus Reactivation in Rheumatic Diseases
Abstract Number: 273

The Risk Factors of Developing Adult T Cell Leukemia (ATL) in Human T Cell Leukemia Virus Type 1 (HTLV-1) Positive Patients with Rheumatoid Arthritis in Endemic Area, Japan; A Retrospective Cohort Study
Abstract Number: 274

Frequency of Chronic Joint Pain Following Chikungunya Infection: A Colombian Cohort Study
Abstract Number: 275

Predictive Factors of Cytomegalovirus Infection in Patients with Connective Tissue Diseases Treated with Immunosuppressive Drugs
Abstract Number: 276

Follow-up of Patients with Musculoskeletal Manifestations Related to Chikungunya Fever
Abstract Number: 277

Rheumatic Conditions Appearing De Novo after Infection with Chikungunya Virus in Venezuelan Patients
Abstract Number: 278

Corticosteroid Use, Biologic Therapy Switching, Smoking and Renal Failure Are Associated with Serious Infections in Rheumatoid Arthritis Patients Treated with Biologics: Data from Two Latin-American Registries
Abstract Number: 279

the Usefulness of Cytomegalovirus Infection Strategy in Patients with Connective-Tissue Disease, Based on the Guidelines of the Japan Society for Hematopoietic Cell Transplantation 2011
Abstract Number: 280

Reasons Why Patients Failed Vaccinations Vs Influenza and Pneumococcus. Monocentric Cross-Sectional Study.
Abstract Number: 281

Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Virus Infection in France
Abstract Number: 282

The Value of Imaging As an Early Noninvasive Test for Prosthetic Joint Septic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].